Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling

Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling

Abstract Background Malignant ventricular arrhythmia (VA) is a major contributor to sudden cardiac death (SCD) in patients with pulmonary arterial hypertension (PAH)-induced right heart failure (RHF). Recently, dapagliflozin (DAPA), a sodium/glucose cotransporter-2 inhibitor (SGLT2i), has been found...

Full description

Bibliographic Details
Main Authors: Jinchun Wu, Tao Liu, Shaobo Shi, Zhixing Fan, Roddy Hiram, Feng Xiong, Bo Cui, Xiaoling Su, Rong Chang, Wei Zhang, Min Yan, Yanhong Tang, He Huang, Gang Wu, Congxin Huang
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Cardiovascular Diabetology
Subjects:
Dapagliflozin
Ventricular arrhythmias
Calcium handling
Right heart failure
Pulmonary arterial hypertension
Monocrotaline
Online Access:https://doi.org/10.1186/s12933-022-01614-5

Internet

https://doi.org/10.1186/s12933-022-01614-5

Similar Items